fig2

Figure 2. Strategies to overcome immunotherapy resistance in MPM. MPM: Malignant pleural mesothelioma; MSLN: mesothelin; CAR-T: chimeric antigen receptor T cell; Atezolizumab: anti-PD-L1 monoclonal antibody; PD-1: programmed cell death protein 1; Nivolumab: anti-PD-1 monoclonal antibody; Pembrolizumab: anti-PD-1 monoclonal antibody; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; Ipilimumab: anti-CTLA-4 monoclonal antibody; TME: tumor microenvironment; Treg: regulatory T cell; TAMs: tumor-associated macrophages; MDSCs: myeloid-derived suppressor cells; TGF-βR: transforming growth factor-β receptor; OT-101: TGF-β2-targeting antisense oligonucleotide; NF2: neurofibromin 2; BAP1: BRCA1-associated protein 1; CDKN2A: cyclin-dependent kinase inhibitor 2A; PD-L1: programmed death-ligand 1; TGF-β: transforming growth factor-β; VEGF: vascular endothelial growth factor; YAP: Yes-associated protein; TAZ: transcriptional coactivator with PDZ-binding motif; ADI-PEG20: PEGylated arginine deiminase; Pegargininase: synonym for ADI-PEG20.